A Study of ProQuad™ in Healthy Children in Korea (V221-023)
NCT ID: NCT00839917
Last Updated: 2017-04-12
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE3
30 participants
INTERVENTIONAL
2008-02-29
2008-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety, Tolerability, and Immunogenicity of 3 Frozen ProQuad Consistency Lots in Healthy Children (V221-012)(COMPLETED)
NCT00985153
A Study of ProQuad in Healthy 4 to 6 Year Old Children (V221-014)
NCT00985166
ProQuad™ Versus M-M-R II™ and VARIVAX™ in Healthy Children (V221-009)(COMPLETED)
NCT00975507
ProQuad Dose Selection Study (V221-011)(COMPLETED)
NCT00986232
Frozen ProQuad Administered Concomitantly Versus Nonconcomitantly With Other Pediatric Vaccines
NCT00984295
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ProQuad™
Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (ProQuad™)
Single administration of 0.5 mL subcutaneous injection
M-M-R™ II and Varivax™
M-M-R™ II and Varivax™
Single administration of 0.5 mL subcutaneous injection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (ProQuad™)
Single administration of 0.5 mL subcutaneous injection
M-M-R™ II and Varivax™
Single administration of 0.5 mL subcutaneous injection
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject has a negative clinical history for measles, mumps, rubella, varicella and zoster
Exclusion Criteria
* Subject has any congenital or acquired immune deficiency, neoplastic disease or depressed immunity
* Subject has a history of seizure disorder
* Subject had exposure to measles, mumps, rubella, varicella and/or zoster in the last 4 weeks
* Subject has received an inactivated vaccine within the past 14 days
* Subject has received a live vaccine within the past 30 days
* Subject has received immune globulin within the past 5 months
* Subject has a recent history of fever (within the last 72 hours)
12 Months
23 Months
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Merck Sharp & Dohme LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Monitor
Role: STUDY_DIRECTOR
Merck Sharp & Dohme LLC
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2009_538
Identifier Type: -
Identifier Source: secondary_id
V221-023
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.